140 related articles for article (PubMed ID: 37575247)
1. Response to SARS-CoV-2 initial series and additional dose vaccine in pediatric patients with predominantly antibody deficiency.
Tandon M; DiGiacomo DV; Zhou B; Hesterberg P; Rosenberg CE; Barmettler S; Farmer JR
Front Immunol; 2023; 14():1217718. PubMed ID: 37575247
[TBL] [Abstract][Full Text] [Related]
2. Response to Severe Acute Respiratory Syndrome Coronavirus 2 Initial Series and Additional Dose Vaccine in Patients With Predominant Antibody Deficiency.
Barmettler S; DiGiacomo DV; Yang NJ; Lam T; Naranbhai V; Dighe AS; Burke KE; Blumenthal KG; Ling M; Hesterberg PE; Saff RR; MacLean J; Ofoman O; Berrios C; St Denis KJ; Lam EC; Gregory D; Iafrate AJ; Poznansky M; Lee H; Balazs A; Pillai S; Farmer JR
J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1622-1634.e4. PubMed ID: 35381395
[TBL] [Abstract][Full Text] [Related]
3. Cellular immune response to SARS-CoV-2 in patients with primary antibody deficiencies.
Mizera D; Dziedzic R; Drynda A; Gradzikiewicz A; Jakieła B; Celińska-Löwenhoff M; Padjas A; Matyja-Bednarczyk A; Zaręba L; Bazan-Socha S
Front Immunol; 2023; 14():1275892. PubMed ID: 37901210
[TBL] [Abstract][Full Text] [Related]
4. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine response in adults with predominantly antibody deficiency.
Zhang AM; Elmoursi A; DiGiacomo DV; Zhou B; Tandon M; Hong JS; Yang NJ; Ong MS; Dighe AS; Berrios C; Poznansky MC; Iafrate AJ; Naranbhai V; Balazs A; Pillai S; Farmer JR; Barmettler S
J Allergy Clin Immunol Glob; 2024 May; 3(2):100234. PubMed ID: 38544577
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 Vaccine Induced Atypical Immune Responses in Antibody Defects: Everybody Does their Best.
Salinas AF; Mortari EP; Terreri S; Quintarelli C; Pulvirenti F; Di Cecca S; Guercio M; Milito C; Bonanni L; Auria S; Romaggioli L; Cusano G; Albano C; Zaffina S; Perno CF; Spadaro G; Locatelli F; Carsetti R; Quinti I
J Clin Immunol; 2021 Nov; 41(8):1709-1722. PubMed ID: 34669144
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 booster vaccination rescues attenuated IgG1 memory B cell response in primary antibody deficiency patients.
Lin FJ; Doss AMA; Davis-Adams HG; Adams LJ; Hanson CH; VanBlargan LA; Liang CY; Chen RE; Monroy JM; Wedner HJ; Kulczycki A; Mantia TL; O'Shaughnessy CC; Raju S; Zhao FR; Rizzi E; Rigell CJ; Dy TB; Kau AL; Ren Z; Turner JS; O'Halloran JA; Presti RM; Fremont DH; Kendall PL; Ellebedy AH; Mudd PA; Diamond MS; Zimmerman O; Laidlaw BJ
Front Immunol; 2022; 13():1033770. PubMed ID: 36618402
[TBL] [Abstract][Full Text] [Related]
7. Defining Clinical and Immunological Predictors of Poor Immune Responses to COVID-19 mRNA Vaccines in Patients with Primary Antibody Deficiency.
Shin JJ; Par-Young J; Unlu S; McNamara A; Park HJ; Shin MS; Gee RJ; Doyle H; Afinogenova Y; Zidan E; Kwah J; Russo A; Mamula M; Hsu FI; Catanzaro J; Racke M; Bucala R; Wilen C; Kang I
J Clin Immunol; 2022 Aug; 42(6):1137-1150. PubMed ID: 35713752
[TBL] [Abstract][Full Text] [Related]
8. Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity.
Bowman KA; Stein D; Shin S; Ferbas KG; Tobin NH; Mann C; Fischinger S; Ollmann Saphire E; Lauffenburger D; Rimoin AW; Aldrovandi G; Alter G
mBio; 2022 Oct; 13(5):e0164722. PubMed ID: 36000735
[TBL] [Abstract][Full Text] [Related]
9. B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies.
Pulvirenti F; Fernandez Salinas A; Milito C; Terreri S; Piano Mortari E; Quintarelli C; Di Cecca S; Lagnese G; Punziano A; Guercio M; Bonanni L; Auria S; Villani F; Albano C; Locatelli F; Spadaro G; Carsetti R; Quinti I
Cells; 2021 Oct; 10(11):. PubMed ID: 34831138
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity.
Steiner S; Schwarz T; Corman VM; Gebert L; Kleinschmidt MC; Wald A; Gläser S; Kruse JM; Zickler D; Peric A; Meisel C; Meyer T; Staudacher OL; Wittke K; Kedor C; Bauer S; Besher NA; Kalus U; Pruß A; Drosten C; Volk HD; Scheibenbogen C; Hanitsch LG
Front Immunol; 2022; 13():840126. PubMed ID: 35359967
[TBL] [Abstract][Full Text] [Related]
11. Quantitative Analysis of SARS-CoV-2 Antibody Levels in Cancer Patients Post Three Doses of Immunization and Prior to Breakthrough COVID-19 Infections.
Macrae K; Martinez-Cajas J; Bessai K; Abdulhamed A; Gong Y
Curr Oncol; 2022 Sep; 29(10):7059-7071. PubMed ID: 36290831
[TBL] [Abstract][Full Text] [Related]
12. Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects.
Wheeler SE; Shurin GV; Yost M; Anderson A; Pinto L; Wells A; Shurin MR
Microbiol Spectr; 2021 Sep; 9(1):e0034121. PubMed ID: 34346750
[TBL] [Abstract][Full Text] [Related]
13. Antibody levels following vaccination against SARS-CoV-2: associations with post-vaccination infection and risk factors in two UK longitudinal studies.
Cheetham NJ; Kibble M; Wong A; Silverwood RJ; Knuppel A; Williams DM; Hamilton OKL; Lee PH; Bridger Staatz C; Di Gessa G; Zhu J; Katikireddi SV; Ploubidis GB; Thompson EJ; Bowyer RCE; Zhang X; Abbasian G; Garcia MP; Hart D; Seow J; Graham C; Kouphou N; Acors S; Malim MH; Mitchell RE; Northstone K; Major-Smith D; Matthews S; Breeze T; Crawford M; Molloy L; Kwong ASF; Doores K; Chaturvedi N; Duncan EL; Timpson NJ; Steves CJ
Elife; 2023 Jan; 12():. PubMed ID: 36692910
[TBL] [Abstract][Full Text] [Related]
14. Increased Seroprevalence and Improved Antibody Responses Following Third Primary SARS-CoV-2 Immunisation: An Update From the COV-AD Study.
Shields AM; Faustini SE; Hill HJ; Al-Taei S; Tanner C; Ashford F; Workman S; Moreira F; Verma N; Wagg H; Heritage G; Campton N; Stamataki Z; Drayson MT; Klenerman P; Thaventhiran JED; Elkhalifa S; Goddard S; Johnston S; Huissoon A; Bethune C; Elcombe S; Lowe DM; Patel SY; Savic S; Richter AG; Burns SO;
Front Immunol; 2022; 13():912571. PubMed ID: 35720400
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects.
Pham MN; Murugesan K; Banaei N; Pinsky BA; Tang M; Hoyte E; Lewis DB; Gernez Y
J Allergy Clin Immunol; 2022 Mar; 149(3):907-911.e3. PubMed ID: 34952033
[TBL] [Abstract][Full Text] [Related]
16. Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial.
Thakkar A; Pradhan K; Duva B; Carreno JM; Sahu S; Thiruthuvanathan V; Campbell S; Gallego S; Bhagat TD; Rivera J; Choudhary G; Olea R; Sabalza M; Shapiro LC; Lee M; Quinn R; Mantzaris I; Chu E; Will B; Pirofski LA; Krammer F; Verma A; Halmos B
Elife; 2023 Mar; 12():. PubMed ID: 36975207
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2-Specific and Functional Cytotoxic CD8 Cells in Primary Antibody Deficiency: Natural Infection and Response to Vaccine.
Gupta S; Agrawal S; Sandoval A; Su H; Tran M; Demirdag Y
J Clin Immunol; 2022 Jul; 42(5):914-922. PubMed ID: 35366743
[TBL] [Abstract][Full Text] [Related]
18. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.
Kennedy NA; Lin S; Goodhand JR; Chanchlani N; Hamilton B; Bewshea C; Nice R; Chee D; Cummings JF; Fraser A; Irving PM; Kamperidis N; Kok KB; Lamb CA; Macdonald J; Mehta S; Pollok RC; Raine T; Smith PJ; Verma AM; Jochum S; McDonald TJ; Sebastian S; Lees CW; Powell N; Ahmad T;
Gut; 2021 Oct; 70(10):1884-1893. PubMed ID: 33903149
[TBL] [Abstract][Full Text] [Related]
19. The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study.
Christensen IE; Jyssum I; Tveter AT; Sexton J; Tran TT; Mjaaland S; Kro GB; Kvien TK; Warren DJ; Jahnsen J; Munthe LA; Haavardsholm EA; Vaage JT; Grødeland G; Lund-Johansen F; Jørgensen KK; Syversen SW; Goll GL; Provan SA
BMC Med; 2022 Oct; 20(1):378. PubMed ID: 36199139
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 Vaccine Responses in Individuals with Antibody Deficiency: Findings from the COV-AD Study.
Shields AM; Faustini SE; Hill HJ; Al-Taei S; Tanner C; Ashford F; Workman S; Moreira F; Verma N; Wagg H; Heritage G; Campton N; Stamataki Z; Klenerman P; Thaventhiran JED; Goddard S; Johnston S; Huissoon A; Bethune C; Elcombe S; Lowe DM; Patel SY; Savic S; Burns SO; Richter AG;
J Clin Immunol; 2022 Jul; 42(5):923-934. PubMed ID: 35420363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
